MiMedx Group (NASDAQ:MDXG) Reaches New 52-Week Low – Here’s Why
by Mitch Edgeman · The Markets DailyMiMedx Group, Inc (NASDAQ:MDXG – Get Free Report)’s stock price hit a new 52-week low during trading on Tuesday . The company traded as low as $3.77 and last traded at $3.86, with a volume of 924041 shares. The stock had previously closed at $3.81.
Analyst Ratings Changes
A number of analysts have recently issued reports on the stock. Lake Street Capital dropped their price objective on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 20th. Citizens Jmp assumed coverage on MiMedx Group in a research note on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 target price on the stock. Citigroup assumed coverage on MiMedx Group in a research report on Monday, February 23rd. They set a “market outperform” rating on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Finally, Cantor Fitzgerald cut their price objective on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, MiMedx Group has a consensus rating of “Moderate Buy” and an average price target of $9.60.
Read Our Latest Analysis on MiMedx Group
MiMedx Group Stock Performance
The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06. The firm’s fifty day moving average is $4.78 and its two-hundred day moving average is $6.12. The firm has a market cap of $586.85 million, a P/E ratio of 12.34 and a beta of 1.65.
MiMedx Group (NASDAQ:MDXG – Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%. Analysts predict that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Trigran Investments Inc. grew its stake in shares of MiMedx Group by 10.4% in the second quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock worth $51,266,000 after acquiring an additional 790,901 shares during the last quarter. Vanguard Group Inc. raised its position in shares of MiMedx Group by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock worth $48,637,000 after purchasing an additional 382,623 shares during the last quarter. State Street Corp raised its position in shares of MiMedx Group by 6.1% in the 4th quarter. State Street Corp now owns 3,813,796 shares of the company’s stock worth $25,819,000 after purchasing an additional 219,190 shares during the last quarter. First Light Asset Management LLC boosted its stake in MiMedx Group by 89.5% in the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after purchasing an additional 1,725,458 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in MiMedx Group by 4.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,479,369 shares of the company’s stock valued at $16,786,000 after purchasing an additional 97,036 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.
MiMedx Group Company Profile
MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.
MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.